135 related articles for article (PubMed ID: 8217599)
1. Retinoids, breast cancer and NK cells.
Villa ML; Ferrario E; Trabattoni D; Formelli F; De Palo G; Magni A; Veronesi U; Clerici E
Br J Cancer; 1993 Nov; 68(5):845-50. PubMed ID: 8217599
[TBL] [Abstract][Full Text] [Related]
2. Breast tissue accumulation of retinamides in a randomized short-term study of fenretinide.
Sabichi AL; Modiano MR; Lee JJ; Peng YM; Xu MJ; Villar H; Dalton WS; Lippman SM
Clin Cancer Res; 2003 Jul; 9(7):2400-5. PubMed ID: 12855611
[TBL] [Abstract][Full Text] [Related]
3. Chemoprevention of skin carcinogenesis by phenylretinamides: retinoid receptor-independent tumor suppression.
Xu H; Cheepala S; McCauley E; Coombes K; Xiao L; Fischer SM; Clifford JL
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):969-79. PubMed ID: 16467112
[TBL] [Abstract][Full Text] [Related]
4. N-(4-hydroxyphenyl)retinamide (4-HPR)-mediated biological actions involve retinoid receptor-independent pathways in human breast carcinoma.
Sheikh MS; Shao ZM; Li XS; Ordonez JV; Conley BA; Wu S; Dawson MI; Han QX; Chao WR; Quick T
Carcinogenesis; 1995 Oct; 16(10):2477-86. PubMed ID: 7586155
[TBL] [Abstract][Full Text] [Related]
5. Plasma retinol level reduction by the synthetic retinoid fenretinide: a one year follow-up study of breast cancer patients.
Formelli F; Carsana R; Costa A; Buranelli F; Campa T; Dossena G; Magni A; Pizzichetta M
Cancer Res; 1989 Nov; 49(21):6149-52. PubMed ID: 2529028
[TBL] [Abstract][Full Text] [Related]
6. Effects of N-(4-hydroxyphenyl)-retinamide on the number and cytotoxicity of natural killer cells in vitamin-A-sufficient and -deficient rats.
Zhao Z; Matsuura T; Popoff K; Ross AC
Nat Immun; 1994; 13(5):280-8. PubMed ID: 7833627
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory effects of fenretinide metabolites N-[4-methoxyphenyl]retinamide (MPR) and 4-oxo-N-(4-hydroxyphenyl)retinamide (3-keto-HPR) on fenretinide molecular targets β-carotene oxygenase 1, stearoyl-CoA desaturase 1 and dihydroceramide Δ4-desaturase 1.
Poliakov E; Samuel W; Duncan T; Gutierrez DB; Mata NL; Redmond TM
PLoS One; 2017; 12(4):e0176487. PubMed ID: 28448568
[TBL] [Abstract][Full Text] [Related]
8. Thymostimulin increases natural cytotoxic activity in patients with breast cancer.
Meneses G; Delgado MA; Perez-Machado MA; Prieto A; Alonso R; Carrion F; Lanzos E; Alvarez-Mon M
Int J Immunopharmacol; 1997 Apr; 19(4):187-93. PubMed ID: 9373769
[TBL] [Abstract][Full Text] [Related]
9. Reduced natural killer cell activity and IL-2 production in malnourished cancer patients.
Villa ML; Ferrario E; Bergamasco E; Bozzetti F; Cozzaglio L; Clerici E
Br J Cancer; 1991 Jun; 63(6):1010-4. PubMed ID: 2069835
[TBL] [Abstract][Full Text] [Related]
10. Comparison of N-(4-hydroxyphenyl)retinamide and all-trans-retinoic acid in the regulation of retinoid receptor-mediated gene expression in human breast cancer cell lines.
Kazmi SM; Plante RK; Visconti V; Lau CY
Cancer Res; 1996 Mar; 56(5):1056-62. PubMed ID: 8640761
[TBL] [Abstract][Full Text] [Related]
11. Retinoid receptor-dependent and independent biological activities of novel fenretinide analogues and metabolites.
Sabichi AL; Xu H; Fischer S; Zou C; Yang X; Steele VE; Kelloff GJ; Lotan R; Clifford JL
Clin Cancer Res; 2003 Oct; 9(12):4606-13. PubMed ID: 14555536
[TBL] [Abstract][Full Text] [Related]
12. Metabolism of N-[4-hydroxyphenyl]retinamide (4-HPR) to N-[4-methoxyphenyl]retinamide (4-MPR) may serve as a biomarker for its efficacy against human breast cancer and melanoma cells.
Mehta RR; Hawthorne ME; Graves JM; Mehta RG
Eur J Cancer; 1998 May; 34(6):902-7. PubMed ID: 9797705
[TBL] [Abstract][Full Text] [Related]
13. Generation of activated killer (AK) cells by recombinant interleukin 2 (rIL 2) in collaboration with interferon-gamma (IFN-gamma).
Itoh K; Shiiba K; Shimizu Y; Suzuki R; Kumagai K
J Immunol; 1985 May; 134(5):3124-9. PubMed ID: 2984283
[TBL] [Abstract][Full Text] [Related]
14. Identification of the fenretinide metabolite 4-oxo-fenretinide present in human plasma and formed in human ovarian carcinoma cells through induction of cytochrome P450 26A1.
Villani MG; Appierto V; Cavadini E; Valsecchi M; Sonnino S; Curley RW; Formelli F
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6265-75. PubMed ID: 15448016
[TBL] [Abstract][Full Text] [Related]
15. N-(4-Hydroxyphenyl)retinamide is more potent than other phenylretinamides in inhibiting the growth of BRCA1-mutated breast cancer cells.
Simeone AM; Deng CX; Kelloff GJ; Steele VE; Johnson MM; Tari AM
Carcinogenesis; 2005 May; 26(5):1000-7. PubMed ID: 15695235
[TBL] [Abstract][Full Text] [Related]
16. Is growth inhibition and induction of apoptosis in lung cancer cell lines by fenretinide [N-(4-hydroxyphenyl)retinamide] sufficient for cancer therapy?
Ohlmann CH; Jung C; Jaques G
Int J Cancer; 2002 Aug; 100(5):520-6. PubMed ID: 12124800
[TBL] [Abstract][Full Text] [Related]
17. Tolerability of the synthetic retinoid Fenretinide (HPR).
Costa A; Malone W; Perloff M; Buranelli F; Campa T; Dossena G; Magni A; Pizzichetta M; Andreoli C; Del Vecchio M
Eur J Cancer Clin Oncol; 1989 May; 25(5):805-8. PubMed ID: 2525470
[TBL] [Abstract][Full Text] [Related]
18. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.
Miller JS; Tessmer-Tuck J; Pierson BA; Weisdorf D; McGlave P; Blazar BR; Katsanis E; Verfaillie C; Lebkowski J; Radford J; Burns LJ
Biol Blood Marrow Transplant; 1997 Apr; 3(1):34-44. PubMed ID: 9209739
[TBL] [Abstract][Full Text] [Related]
19. N-(4-hydroxyphenyl)retinamide (Fenretinide) in combination with retinoic acid enhances differentiation and retinoylation of proteins.
Takahashi N; Sausville EA; Breitman TR
Clin Cancer Res; 1995 Jun; 1(6):637-42. PubMed ID: 9816026
[TBL] [Abstract][Full Text] [Related]
20. Chemoprevention of breast cancer with retinoids.
Veronesi U; De Palo G; Costa A; Formelli F; Marubini E; Del Vecchio M
J Natl Cancer Inst Monogr; 1992; (12):93-7. PubMed ID: 1535505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
